KesiciSTanyıldızMYetimakmanFBayrakciB. Anovel treatment strategy for severe Guillain-Barré syndrome: Zipper method. J Child Neurol. 2019;34(5):277–283.
2.
Van der MecheFGSchmitzPI. Arandomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med. 1992;326:1123–1129.
3.
RaphaelJCChevretSHughesRA, et al.Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2002;2:CD001798.
4.
Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet. 1997;349(9047):225–230.
5.
HughesRAWijdicksEFBarohnR, et al.Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61:736–740.
6.
HughesRASwanAVRaphaelJC, et al.Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain. 2007;130:2245–2257.
7.
Oczko-WalkerMManousakisGWangSMalterJSWaclawikAJ. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency. J Clin Neuromuscul Dis. 2010;12(2):55–61.
8.
RamakrishnanSMustareVPhilipMThennarasuKPeriyavanS. Treatment-related fluctuations in Guillain Barre syndrome and the conundrum of additional cycles of plasmapheresis. Ann Indian Acad Neurol. 2017;20(4):372–377.
9.
VerboonCvan den BergBCornblathDR, et al; IGOS Consortium. Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. J Neurol Neurosurg Psychiatry. 2019;91(2):113–121.
10.
TatayJDíez-TejedorEFrankATejadaJMarreroCBarreiroP. Association of plasmapheresis and high doses of intravenous immunoglobulins in the treatment of myasthenia gravis. Rev Neurol. 1997;25(145):1402–1406.
